The efficacy and safety of venetoclax and azacytidine combination treatment in patients with acute myeloid leukemia and myelodysplastic syndrome: systematic review and meta-analysis

References

• Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373(12):1136–52.
   PubMed Web of Science ®Google Scholar
• Acute Myeloid Leukemia (AML) SEER 22 2015–2019, All Races, Both Sexes.
   Google Scholar
• Burnett AK, Hills RK, Russell N. Twenty five years of UK trials in acute myeloid leukaemia: what have we learned? Br J Haematol. 2020;188(1):86–100.
   PubMed Web of Science ®Google Scholar
• Urbino I, Secreto C, Olivi M, et al. Evolving therapeutic approaches for older patients with acute myeloid leukemia in 2021. Cancers (Basel). 2021;13(20):5075.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Shallis RM, Wang R, et al. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019;34:1–15.
   PubMed Web of Science ®Google Scholar
• Surveillance Research Program, National Cancer Institute. All cancer sites combined: recent trends in SEER age-adjusted incidence rates, 2000-2019 by sex, delay-adjusted SEER incidence rate, all races, all ages. Accessed June 22, 2022.
   Google Scholar
• Zeidan AM, Shallis RM, Wang R, et al. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019;34:1–15.
   PubMed Web of Science ®Google Scholar
• Daver N, Wei AH, Pollyea DA, et al. New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J. 2020;10(10):107.
   PubMed Web of Science ®Google Scholar
• Bazinet A, Bravo GM. New approaches to myelodysplastic syndrome treatment. Curr Treat Options Oncol. 2022;23(5):668–687.
   PubMed Web of Science ®Google Scholar
• Palmieri R, Paterno G, De Bellis E, et al. Therapeutic choice in older patients with acute myeloid leukemia: A matter of fitness. Cancers (Basel). 2020;12(1):120.
   PubMed Web of Science ®Google Scholar
• Lever JR, Fergason-Cantrell EA. Allosteric modulation of sigma receptors by BH3 mimetics ABT-737, ABT-263 (Navitoclax) and ABT-199 (Venetoclax). Pharmacol Res. 2019;142:87–100.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Yang D, Pillai R, et al. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Am J Hematol. 2019;94(10):E253–E255.
   PubMed Web of Science ®Google Scholar
• De Bellis E, Imbergamo S, Candoni A, et al. Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience. Leuk Res. 2022;114:106803.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Shinagawa A, DiNardo CD, et al. Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Jpn J Clin Oncol. 2022;52(1):29–38.
   PubMed Web of Science ®Google Scholar
• Saygin C, Carraway HE. Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021;48:100791.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003 Dec 15;21(24):4642–9.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–25.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03 (2010) Us Department of Health and Human Services. National Institutes of Health National Cancer Institute. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5 ( 7.pdf.
   Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. Cochrane bias methods group; cochrane statistical methods group. The cochrane collaboration's tool for assessing risk of bias in randomised trials. Br Med J. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712–6.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. Br Med J. 2003;327(7414):557–60.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Pratz K, Letai A, et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. Am J Hematol 2021;96(2):208–217.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
   PubMed Web of Science ®Google Scholar
• Cherry EM, Abbott D, Amaya M, et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv 2021; 5(24): 5565–5573.
   PubMed Web of Science ®Google Scholar
• Byrne M, Danielson N, Sengsayadeth S, et al. The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia. Am J Hematol 2020;95(9):1006–1014.
   PubMed Web of Science ®Google Scholar
• Labrador J, Saiz-Rodriguez M, de Miguel D, et al. Use of venetoclax in patients with relapsed or refractory acute myeloid leukemia: The PETHEMA registry experience. Cancers (Basel). 2022;14(7):1734.
   PubMed Web of Science ®Google Scholar
• Jacqueline S, Safety GM. Efficacy, and patient-reported outcomes of venetoclax in combination With azacitidine for the treatment of patients With higher-risk myelodysplastic syndrome: A phase 1b study. Clin Adv Hematol Oncol. 2020;19(1):14–16.
   Web of Science ®Google Scholar
• DiNardo CL, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216–228.
   PubMed Web of Science ®Google Scholar
• Matthews AH, Perl AE, Luger SM, et al. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv. 2022;Jul 12;6(13):3997–4005.
   Web of Science ®Google Scholar
• Ucar MA, Ozet G, Koyuncu MB, et al. Real world results of venetoclax combined with hypomethylating agents in relapsed/refractory AML. Eur Rev Med Pharmacol Sci. 2021;25(21):6557–6565.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Pollyea DA, Garcia JS, et al. A phase 1b study evaluating the safety and efficacy of venetoclax As monotherapy or in combination with azacitidine for the treatment of relapsed/refractory myelodysplastic syndrome. Blood. 2019;134:565.
   Web of Science ®Google Scholar
• Mirgh S, Sharma A, Shaikh M, et al. Hypomethylating agents + venetoclax induction therapy in acute myeloid leukemia unfit for intensive chemotherapy - novel avenues for lesser venetoclax duration and patients with baseline infections from a developing country. Am J Blood Res. 2021;11(3):290–302.
   PubMed Web of Science ®Google Scholar
• Taniguchi S, Yamauchi T, Choi I, et al. Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings. Jpn J Clin Oncol 2021;51(6):857–864.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Stevens BM, Winters A, et al. Venetoclax (Ven) with azacitidine (Aza) for untreated elderly acute myeloid leukemia (AML) patients (Pts) unfit for induction chemotherapy: single center clinical experience and mechanistic insights from correlative studies. Blood. 2017;130:181.
   PubMed Web of Science ®Google Scholar
• Winters AC, Gutman JA, Purev E, et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv 2019; 3(20): 2911–2919.
   PubMed Web of Science ®Google Scholar
• Wei AH, Garcia JS, Borate U, et al. A phase 1b study evaluating the safety and efficacy of venetoclax in combination with azacitidine in treatment-naive patients with higher-risk myelodysplastic syndrome. Blood. 2019;134:568.
   PubMed Web of Science ®Google Scholar
• Aktimur SH, Gunes AK, Akidan O, et al. Efficacy of the Combination of Venetoclax and Azacitidine in Elderly of Frail Relapsed/Refractory Patients with Acute Myeloid Leukemia, First Multi-Institutional Real World Experience from Turkey. UHOD - Uluslar Hematol-Onkol Derg. 2020;30(4):213–221.
   Web of Science ®Google Scholar
• Lou YJ, Shao L, Mao LP, et al. Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study. Leuk Res 2020 Apr;91:106317.
   PubMed Web of Science ®Google Scholar
• Labrador J, Saiz-Rodríguez M, de Miguel D, et al. Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience. Cancers (Basel). 2022;14(7):1734.
   Google Scholar
• Liu B, Guo Y, Deng L, et al. The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis. Hematology. 2020;25(1):414–423.
   PubMed Web of Science ®Google Scholar
• Liu W, Zhou Z, Chen L, et al. Comparison of azacitidine and decitabine in myelodysplastic syndromes and acute myeloid leukemia: A network meta-analysis. Clin Lymphoma Myeloma Leuk. 2021;21(6):e530–e544.
   PubMed Web of Science ®Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291–9.
   PubMed Web of Science ®Google Scholar
• Kirtane K, Lee SJ. Racial and ethnic disparities in hematologic malignancies. Blood. 2017;130(15):1699–1705.
   PubMed Web of Science ®Google Scholar
• Tsai CH, Hou HA, Tang JL, et al. Genetic alterations and their clinical implications in older patients with acute myeloid leukemia. Leukemia. 2016;30(7):1485–92.
   PubMed Web of Science ®Google Scholar
• Pei S, Pollyea DA, Gustafson A, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10(4):536–551.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Riley-Gillis B, Han L, et al. Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther. 2022;7(1):51.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Othus M, List AF, et al. Randomized phase II study of azacitidine alone or in combination With lenalidomide or With vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American intergroup study SWOG S1117. J Clin Oncol. 2017;35(24):2745–2753.
   PubMed Web of Science ®Google Scholar
• Prebet T, Sun Z, Figueroa ME, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. J Clin Oncol. 2014;32(12):1242–8.
   PubMed Web of Science ®Google Scholar
• Vives S, Martinez-Cuadron D, Bergua Burgues J, et al. A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia. Cancer. 2021;127(12):2003–2014.
   PubMed Web of Science ®Google Scholar